American Financial Group Inc vs Quest Diagnostics Inc — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.97B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 2.2× American Financial Group Inc's market cap, and American Financial Group Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AFG | DGX | |
|---|---|---|
Market Cap | $11.97B | $26.21B |
Sector | Financials | Health |
52-Week High | $148.71 | $238.50 |
52-Week Low | $124.18 | $173.49 |
Enterprise Value | $12.35B | $31.97B |
Dividend Yield | 2.44% | 1.45% |
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.77, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 projections show improved profitability. A dividend of $0.88 per share is scheduled for payment in July 2026.
AFG presents a positive outlook with analyst consensus price target of $160.67, implying potential upside. Strengths include consistent earnings beats and robust ROE of 20.41%. Risks involve earnings volatility, as seen in Q1 2026 miss, and competitive insurance market pressures. Institutional activity is mixed, with some reducing holdings while others increase positions. The stock is a hold for growth-oriented investors monitoring earnings consistency.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Trailing returns across standard periods
Latest headlines on both assets
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →